{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:21:29Z","timestamp":1747207289378,"version":"3.40.5"},"reference-count":60,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CHYR"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>The relationship between diabetes and risk of heart failure has been described in previous\ntrials, releasing the importance of the hyperglycemic state that, added to other risk factors, favors\nthe development of coronary heart disease. The mechanism by which, in the absence of hypertension,\nobesity and\/or dyslipidemia, diabetic patients develop cardiomyopathy has been less\nstudied.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Recently, the Sodium Glucose Co-transporter type 2 inhibitors (SGLT2 inhibitors) used for the\ntreatment of heart failure patients with or without diabetes has been a breakthrough in the field of\nmedicine.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>This review describes the established pathophysiology of diabetic cardiomyopathy and SGLT2 inhibitors,\ntheir mechanisms of action, and benefits in this group of patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573402117666210406111927","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T04:35:35Z","timestamp":1617770135000},"page":"85-93","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Heart Failure and Diabetes: Perspective of a Dangerous Association"],"prefix":"10.2174","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4542-0012","authenticated-orcid":true,"given":"Liliana E.","family":"Favaloro","sequence":"first","affiliation":[{"name":"Department of Heart Failure, Hospital Universitario Fundaci\u00f3n Favaloro, Buenos Aires,Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4873-9096","authenticated-orcid":true,"given":"Roxana D.","family":"Ratto","sequence":"additional","affiliation":[{"name":"Department of Heart Failure, Hospital Universitario Fundaci\u00f3n Favaloro, Buenos Aires,Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0567-3656","authenticated-orcid":true,"given":"Carla","family":"Musso","sequence":"additional","affiliation":[{"name":"Department of Diabetes Metabolic, Hospital Universitario Fundaci\u00f3n Favaloro, Buenos Aires,Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"1","volume":"84","year":"2016","unstructured":"Sociedad Argentina de Cardiolog&#xED;a. Consenso De Insuficiencia Card&#xED;aca Cr&#xF3;nica. Rev Argent Cardiol 2016,84(3),1-50","journal-title":"Rev Argent Cardiol"},{"year":"2019","unstructured":"IDF Diabetes Atlas - 2019 International Diabetes Federation (IDF)2019","journal-title":"IDF Diabetes Atlas - 2019","key":"ref=2"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.diabres.2013.07.004","volume":"101","author":"Faden G.","year":"2013","unstructured":"Faden G.; Faganello G.; De Feo S.; Berlinghieri N.; Tarantini L.; Di Lenarda A.; Faggiano P.; Cioffi G.; The increasing detection of asymptomatic left ventricular dysfunction in patients with Type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study. Diabetes Res Clin Pract 2013,101(3),309-316","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1007\/s00125-012-2579-0","volume":"55","author":"Boonman-de Winter L.J.M.","year":"2012","unstructured":"Boonman-de Winter L.J.M.; Rutten F.H.; Cramer M.J.M.; Landman M.J.; Liem A.H.; Rutten G.E.H.M.; Hoes A.W.; High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with Type 2 diabetes. Diabetologia 2012,55(8),2154-2162","journal-title":"Diabetologia"},{"key":"ref=5","first-page":"73","volume":"38","author":"Sherrill J.W.","year":"1933","unstructured":"Sherrill J.W.; Cardiovascular disease in diabetes mellitus: An analysis of four hundred and twenty-five cases. Cal West Med 1933,38(2),73-78","journal-title":"Cal West Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","volume":"241","author":"Kannel W.B.","year":"1979","unstructured":"Kannel W.B.; McGee D.L.; Diabetes and cardiovascular disease. The framingham study. JAMA 1979,241(19),2035-2038","journal-title":"JAMA"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/j.ihj.2014.10.130","volume":"66","author":"Senthil A.N.","year":"2014","unstructured":"Senthil A.N.; Ravishankar G.; Ravi M.S.; Pattern of coronary artery disease in symptomatic Type 2 diabetic subjects in the contemporary era and the difference from past studies. Indian Heart J 2014,66,S46","journal-title":"Indian Heart J"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"Einarson T.R.","year":"2018","unstructured":"Einarson T.R.; Acs A.; Ludwig C.; Panton U.H.; Prevalence of cardiovascular disease in Type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol 2018,17(1),83","journal-title":"Cardiovasc Diabetol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"Rawshani A.","year":"2017","unstructured":"Rawshani A.; Rawshani A.; Franz&#xE9;n S.; Eliasson B.; Svensson A-M.; Miftaraj M.; McGuire D.K.; Sattar N.; Rosengren A.; Gudbj&#xF6;rnsdottir S.; Mortality and cardiovascular disease in Type 1 and Type 2 diabetes. N Engl J Med 2017,376(15),1407-1418","journal-title":"N Engl J Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.2337\/dc18-0831","volume":"41","author":"Cheng Y.J.","year":"2018","unstructured":"Cheng Y.J.; Imperatore G.; Geiss L.S.; Saydah S.H.; Albright A.L.; Ali M.K.; Gregg E.W.; Trends and disparities in cardiovascular mortality among U.S. Adults with and without self-reported diabetes, 1988\u20132015. Diabetes Care 2018,41(11),2306-2315","journal-title":"Diabetes Care"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","volume":"3","author":"Shah A.D.","year":"2015","unstructured":"Shah A.D.; Langenberg C.; Rapsomaniki E.; Denaxas S.; Pujades-Rodriguez M.; Gale C.P.; Deanfield J.; Smeeth L.; Timmis A.; Hemingway H.; Type 2 diabetes and incidence of cardiovascular diseases: A cohort study in 1.9 million people. Lancet Diabetes Endocrinol 2015,3(2),105-113","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1161\/01.CIR.103.22.2668","volume":"103","author":"Iribarren C.","year":"2001","unstructured":"Iribarren C.; Karter A.J.; Go A.S.; Ferrara A.; Liu J.Y.; Sidney S.; Selby J.V.; Glycemic control and heart failure among adult patients with diabetes. Circulation 2001,103(22),2668-2673","journal-title":"Circulation"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2125.1999.00092.x","volume":"48","author":"King P","year":"1999","unstructured":"King P; Peacock I; Donnelly R.; The UK Prospective Diabetes Study (UKPDS): Clinical and therapeutic implications for Type 2 diabetes. Br J Clin Pharmacol 1999,48,643-648","journal-title":"Br J Clin Pharmacol"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jacc.2020.01.017","volume":"75","author":"Alexander CM","year":"2020","unstructured":"Alexander CM; Is heart failure still the frequent, forgotten, and often fatal complication of diabetes? J Am Coll Cardiol 2020,75,1263-1265","journal-title":"J Am Coll Cardiol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"Jia G.","year":"2018","unstructured":"Jia G.; Hill M.A.; Sowers J.R.; Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity. Circ Res 2018,122(4),624-638","journal-title":"Circ Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jacc.2018.11.033","volume":"73","author":"McHugh K.","year":"2019","unstructured":"McHugh K.; DeVore A.D.; Wu J.; Matsouaka R.A.; Fonarow G.C.; Heidenreich P.A.; Yancy C.W.; Green J.B.; Altman N.; Hernandez A.F.; Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review. J Am Coll Cardiol 2019,73(5),602-611","journal-title":"J Am Coll Cardiol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.2337\/diacare.26.8.2433","volume":"26","author":"Bell D.S.H.","year":"2003","unstructured":"Bell D.S.H.; Heart failure: The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003,26(8),2433-2441","journal-title":"Diabetes Care"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ejhf.1170","volume":"20","author":"Seferovi\u0107 P.M.","year":"2018","unstructured":"Seferovi\u0107 P.M.; Petrie M.C.; Filippatos G.S.; Anker S.D.; Rosano G.; Bauersachs J.; Paulus W.J.; Komajda M.; Cosentino F.; de Boer R.A.; Farmakis D.; Doehner W.; Lambrinou E.; Lopatin Y.; Piepoli M.F.; Theodorakis M.J.; Wiggers H.; Lekakis J.; Mebazaa A.; Mamas M.A.; Tsch&#xF6;pe C.; Hoes A.W.; Seferovi\u0107 J.P.; Logue J.; McDonagh T.; Riley J.P.; Milinkovi\u0107 I.; Polovina M.; van Veldhuisen D.J.; Lainscak M.; Maggioni A.P.; Ruschitzka F.; McMurray J.J.V.; Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018,20(5),853-872","journal-title":"Eur J Heart Fail"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"Zinman B.","year":"2015","unstructured":"Zinman B.; Wanner C.; Lachin J.M.; Fitchett D.; Bluhmki E.; Hantel S.; Mattheus M.; Devins T.; Johansen O.E.; Woerle H.J.; Broedl U.C.; Inzucchi S.E.; Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med 2015,373(22),2117-2128","journal-title":"N Engl J Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","volume":"17","author":"Sato T.","year":"2018","unstructured":"Sato T.; Aizawa Y.; Yuasa S.; Kishi S.; Fuse K.; Fujita S.; Ikeda Y.; Kitazawa H.; Takahashi M.; Sato M.; Okabe M.; The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol 2018,17(1),6","journal-title":"Cardiovasc Diabetol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"McMurray J.J.V.","year":"2019","unstructured":"McMurray J.J.V.; Solomon S.D.; Inzucchi S.E.; K&#xF8;ber L.; Kosiborod M.N.; Martinez F.A.; Ponikowski P.; Sabatine M.S.; Anand I.S.; B&#x11B;lohl&#xE1;vek J.; B&#xF6;hm M.; Chiang C.E.; Chopra V.K.; de Boer R.A.; Desai A.S.; Diez M.; Drozdz J.; Duk&#xE1;t A.; Ge J.; Howlett J.G.; Katova T.; Kitakaze M.; Ljungman C.E.A.; Merkely B.; Nicolau J.C.; O\u2019Meara E.; Petrie M.C.; Vinh P.N.; Schou M.; Tereshchenko S.; Verma S.; Held C.; DeMets D.L.; Docherty K.F.; Jhund P.S.; Bengtsson O.; Sj&#xF6;strand M.; Langkilde A.M.; Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019,381(21),1995-2008","journal-title":"N Engl J Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0140-6736(54)90924-1","volume":"266","author":"Lundbaek K.","year":"1954","unstructured":"Lundbaek K.; Diabetic angiopathy: A specific vascular disease. Lancet 1954,266(6808),377-379","journal-title":"Lancet"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","volume":"30","author":"Rubler S.","year":"1972","unstructured":"Rubler S.; Dlugash J.; Yuceoglu Y.Z.; Kumral T.; Branwood A.W.; Grishman A.; New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972,30(6),595-602","journal-title":"Am J Cardiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4093\/dmj.2019.0185","volume":"44","author":"Gollmer J.","year":"2020","unstructured":"Gollmer J.; Zirlik A.; Bugger H.; Mitochondrial mechanisms in diabetic cardiomyopathy. Diabetes Metab J 2020,44,33-35","journal-title":"Diabetes Metab J"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.3390\/ijms20133299","volume":"20","author":"Filardi T.","year":"2019","unstructured":"Filardi T.; Ghinassi B.; Di Baldassarre A.; Tanzilli G.; Morano S.; Lenzi A.; Cardiomyopathy associated with diabetes: The central role of the cardiomyocyte. Int J Mol Sci 2019,20(13),3299","journal-title":"Int J Mol Sci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","volume":"57","author":"Bugger H.","year":"2014","unstructured":"Bugger H.; Abel E.D.; Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014,57(4),660-671","journal-title":"Diabetologia"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fgene.2014.00185","volume":"5","author":"Zhou Q.","year":"2014","unstructured":"Zhou Q.; Lv D.; Chen P.; MicroRNAs in diabetic cardiomyopathy and clinical perspectives. Front Genet 2014,5,185","journal-title":"Front Genet"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.pharmthera.2014.01.003","volume":"142","author":"Huynh K.","year":"2014","unstructured":"Huynh K.; Bernardo B.C.; McMullen J.R.; Ritchie R.H.; Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther 2014,142,375-415","journal-title":"Pharmacol Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2174\/157339910790909396","volume":"6","author":"Masuo K.","year":"2010","unstructured":"Masuo K.; Rakugi H.; Ogihara T.; Esler M.D.; Lambert G.W.; Cardiovascular and renal complications of Type 2 diabetes in obesity: Role of sympathetic nerve activity and insulin resistance. Curr Diabetes Rev 2010,6(2),58-67","journal-title":"Curr Diabetes Rev"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1210\/en.2012-1780","volume":"153","author":"Shen J.Z.","year":"2012","unstructured":"Shen J.Z.; Young M.J.; Corticosteroids, heart failure, and hypertension: A role for immune cells? Endocrinology 2012,153(12),5692-5700","journal-title":"Endocrinology"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/HJH.0b013e3283331169","volume":"28","author":"de Simone G.","year":"2010","unstructured":"de Simone G.; Devereux R.B.; Chinali M.; Lee E.T.; Galloway J.M.; Barac A.; Panza J.A.; Howard B.V.; Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. J Hypertens 2010,28(2),353-360","journal-title":"J Hypertens"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1056\/NEJMcp1511175","volume":"375","author":"Redfield M.M.","year":"2016","unstructured":"Redfield M.M.; Heart failure with preserved ejection fraction. N Engl J Med 2016,375(19),1868-1877","journal-title":"N Engl J Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1161\/CIRCULATIONAHA.110.981431","volume":"123","author":"De Keulenaer G.W.","year":"2011","unstructured":"De Keulenaer G.W.; Brutsaert D.L.; Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation 2011,123(18),1996-2004","journal-title":"Circulation"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","volume":"36","author":"Seferovi\u0107 P.M.","year":"2015","unstructured":"Seferovi\u0107 P.M.; Paulus W.J.; Clinical diabetic cardiomyopathy: A two-faced disease with restrictive and dilated phenotypes. Eur Heart J 2015,36(27),1718-1727","journal-title":"Eur Heart J"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"Zelniker TA","year":"2020","unstructured":"Zelniker TA; Braunwald E; Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol 2020,75,422-434","journal-title":"J Am Coll Cardiol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11886-019-1165-1","volume":"21","author":"Scheen A.J.","year":"2019","unstructured":"Scheen A.J.; Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure. Curr Cardiol Rep 2019,21(8),70","journal-title":"Curr Cardiol Rep"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/jch.14131","volume":"23","author":"Okada K.","year":"2021","unstructured":"Okada K.; Hoshide S.; Kato M.; Kanegae H.; Ishibashi S.; Kario K.; Safety and efficacy of empagliflozin in elderly Japanese patients with Type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study. J Clin Hypertens (Greenwich) 2021,23(4),860-869","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","volume":"139","author":"Kario K.","year":"2019","unstructured":"Kario K.; Okada K.; Kato M.; Twenty-four-hour blood pressure-lowering effect of a sodium-glucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: Results from the randomized, placebo-controlled SACRA Study. Circulation 2019,139(18),2089-2097","journal-title":"Circulation"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/jch.13988","volume":"22","author":"Kario K.","year":"2020","unstructured":"Kario K.; Okada K.; Murata M.; Suzuki D.; Yamagiwa K.; Abe Y.; Usui I.; Tsuchiya N.; Iwashita C.; Harada N.; Okawara Y.; Ishibashi S.; Hoshide S.; Effects of luseogliflozin on arterial properties in patients with Type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study. J Clin Hypertens (Greenwich) 2020,22(9),1585-1593","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1111\/jch.13367","volume":"20","author":"Kario K.","year":"2018","unstructured":"Kario K.; Hoshide S.; Okawara Y.; Tomitani N.; Yamauchi K.; Ohbayashi H.; Itabashi N.; Matsumoto Y.; Kanegae H.; Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with Type 2 diabetes mellitus: The SHIFT-J study. J Clin Hypertens (Greenwich) 2018,20(10),1527-1535","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"Santos-Gallego C.G.","year":"2019","unstructured":"Santos-Gallego C.G.; Requena-Ibanez J.A.; San Antonio R.; Ishikawa K.; Watanabe S.; Picatoste B.; Flores E.; Garcia-Ropero A.; Sanz J.; Hajjar R.J.; Fuster V.; Badimon J.J.; Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol 2019,73(15),1931-1944","journal-title":"J Am Coll Cardiol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1089\/dia.2019.0212","volume":"21","author":"Maruyama T.","year":"2019","unstructured":"Maruyama T.; Takashima H.; Oguma H.; Nakamura Y.; Ohno M.; Utsunomiya K.; Furukawa T.; Tei R.; Abe M.; Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease. Diabetes Technol Ther 2019,21(12),713-720","journal-title":"Diabetes Technol Ther"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"Uthman L.","year":"2018","unstructured":"Uthman L.; Baartscheer A.; Bleijlevens B.; Schumacher C.A.; Fiolet J.W.T.; Koeman A.; Jancev M.; Hollmann M.W.; Weber N.C.; Coronel R.; Zuurbier C.J.; Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: Inhibition of Na\/H exchanger, lowering of cytosolic Na and vasodilation. Diabetologia 2018,61(3),722-726","journal-title":"Diabetologia"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.4070\/kcj.2019.0180","volume":"49","author":"Oh C.M.","year":"2019","unstructured":"Oh C.M.; Cho S.; Jang J.Y.; Kim H.; Chun S.; Choi M.; Park S.; Ko Y.G.; Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure. Korean Circ J 2019,49(12),1183-1195","journal-title":"Korean Circ J"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12933-019-0914-1","volume":"18","author":"Zhang N.","year":"2019","unstructured":"Zhang N.; Feng B.; Ma X.; Sun K.; Xu G.; Zhou Y.; Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovasc Diabetol 2019,18(1),107","journal-title":"Cardiovasc Diabetol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2337\/dci19-0074","volume":"43","author":"Packer M.","year":"2020","unstructured":"Packer M.; SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: A paradigm shift in understanding their mechanism of action. Diabetes Care 2020,43(3),508-511","journal-title":"Diabetes Care"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"Neal B.","year":"2017","unstructured":"Neal B.; Perkovic V.; Mahaffey K.W.; de Zeeuw D.; Fulcher G.; Erondu N.; Shaw W.; Law G.; Desai M.; Matthews D.R.; Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med 2017,377(7),644-657","journal-title":"N Engl J Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"Wiviott S.D.","year":"2019","unstructured":"Wiviott S.D.; Raz I.; Bonaca M.P.; Mosenzon O.; Kato E.T.; Cahn A.; Silverman M.G.; Zelniker T.A.; Kuder J.F.; Murphy S.A.; Bhatt D.L.; Leiter L.A.; McGuire D.K.; Wilding J.P.H.; Ruff C.T.; Gause-Nilsson I.A.M.; Fredriksson M.; Johansson P.A.; Langkilde A.M.; Sabatine M.S.; Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N Engl J Med 2019,380(4),347-357","journal-title":"N Engl J Med"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","volume":"139","year":"2019","unstructured":"Effect of dapagliflozin on heart failure and mortality in Type 2 diabetes mellitus. Circulation Kato ET, Silverman MG, Mosenzon O, et al 2019,139(22),2528-36","journal-title":"Circulation"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","volume":"13","author":"DeFronzo R.A.","year":"2017","unstructured":"DeFronzo R.A.; Norton L.; Abdul-Ghani M.; Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 2017,13,11-26","journal-title":"Nat Rev Nephrol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"40","DOI":"10.17925\/EE.2018.14.2.40","volume":"14","author":"Fitchett D.H.","year":"2018","unstructured":"Fitchett D.H.; Empagliflozin and cardio-renal outcomes in patients with Type 2 diabetes and cardiovascular disease - implications for clinical practice. Eur Endocrinol 2018,14(2),40-49","journal-title":"Eur Endocrinol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"Perkovic V.","year":"2019","unstructured":"Perkovic V.; Jardine M.J.; Neal B.; Bompoint S.; Heerspink H.J.L.; Charytan D.M.; Edwards R.; Agarwal R.; Bakris G.; Bull S.; Cannon C.P.; Capuano G.; Chu P.L.; de Zeeuw D.; Greene T.; Levin A.; Pollock C.; Wheeler D.C.; Yavin Y.; Zhang H.; Zinman B.; Meininger G.; Brenner B.M.; Mahaffey K.W.; Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy. N Engl J Med 2019,380(24),2295-2306","journal-title":"N Engl J Med"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"Heerspink H.J.L.","year":"2020","unstructured":"Heerspink H.J.L.; Stef&#xE1;nsson B.V.; Correa-Rotter R.; Chertow G.M.; Greene T.; Hou F-F.; Mann J.F.E.; McMurray J.J.V.; Lindberg M.; Rossing P.; Sj&#xF6;str&#xF6;m C.D.; Toto R.D.; Langkilde A.M.; Wheeler D.C.; Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020,383(15),1436-1446","journal-title":"N Engl J Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.mayocp.2019.07.008","volume":"95","author":"Klajda M.D.","year":"2020","unstructured":"Klajda M.D.; Scott C.G.; Rodeheffer R.J.; Chen H.H.; Diabetes mellitus is an independent predictor for the development of heart failure: A population study. Mayo Clin Proc 2020,95(1),124-133","journal-title":"Mayo Clin Proc"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jacbts.2018.04.003","volume":"3","author":"Packer M.","year":"2018","unstructured":"Packer M.; Potentiation of insulin signaling contributes to heart failure in Type 2 diabetes: A hypothesis supported by both mechanistic studies and clinical trials. JACC Basic Transl Sci 2018,3(3),415-419","journal-title":"JACC Basic Transl Sci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"Wanner C.","year":"2016","unstructured":"Wanner C.; Inzucchi S.E.; Lachin J.M.; Fitchett D.; von Eynatten M.; Mattheus M.; Johansen O.E.; Woerle H.J.; Broedl U.C.; Zinman B.; Empagliflozin and progression of kidney disease in Type 2 diabetes. N Engl J Med 2016,375(4),323-334","journal-title":"N Engl J Med"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pcad.2020.04.003","volume":"63","author":"Kario K.","year":"2020","unstructured":"Kario K.; Ferdinand K.C.; O\u2019Keefe J.H.; Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. Prog Cardiovasc Dis 2020,63,249-262","journal-title":"Prog Cardiovasc Dis"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/jch.13229","volume":"20","author":"Kario K","year":"2018","unstructured":"Kario K; Weber M; Ferrannini E; Nocturnal hypertension in diabetes: Potential target of sodium\/glucose cotransporter 2 (SGLT2) inhibition. J Clin Hypertens 2018,20,424-428","journal-title":"J Clin Hypertens"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc21-S009","volume":"44","year":"2021","unstructured":"Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes 2021. Diabetes Care 2021,44(Suppl. 1),S111-S124","journal-title":"Diabetes Care"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1111\/jch.14077","volume":"22","author":"Kario K","year":"2020","unstructured":"Kario K; Harada N; Hoshide S.; Randomized, &#x201C;head-to-head&#x201D; studies comparing different SGLT2 inhibitors are definitely needed. J Clin Hypertens 2020,22,2391-2392","journal-title":"J Clin Hypertens"}],"container-title":["Current Hypertension Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/192699","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/192699\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/192699","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T19:36:04Z","timestamp":1649878564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/192699\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573402117666210406111927","relation":{},"ISSN":["1573-4021"],"issn-type":[{"type":"print","value":"1573-4021"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}